Chris Yamamoto

Chris Yamamoto has 20 years of mergers and acquisitions, strategy and investment experience in the medical technology, life sciences and industrials sectors having completed numerous transactions amounting to over $50 billion in value.

Chris currently serves as Senior Vice President of Corporate Development & Strategy at Bioventus, an orthopedics and regenerative medicine company, and is responsible for group functions, including strategy, business development, integration, market access, reimbursement, pricing and market insights.

Prior to Bioventus, Chris was Vice President & Managing Director of Corporate Development at Becton Dickinson. During his tenure at Becton Dickinson, Chris played an instrumental role in transforming the company through two large-scale acquisitions, executing nearly 30 tuck-ins and equity investments and divesting a number of non-core businesses.

Prior to Becton Dickinson, Chris was a Vice President at The Blackstone Group. Chris also worked at Fox Paine, Thoma Cressey, UBS Investment Bank and other institutions.

Chris holds a Bachelor of Arts degree in Economics from Williams College.